Clinical and biological effects of gefitinib in EGFR fish positive/phospho-AKT positive or never smoker non-small cell lung cancer (NSCLC): Results of the ONCOBELL trial

被引：0
|
作者：
Cappuzzo, F.
Toschi, L.
Trisolini, R.
Bartolini, S.
Magrini, E.
Domenichini, I
Metro, G.
Crino, L.
Ciardiello, F.
Varella-Garcia, M.
机构：
[1] Univ Bologna, Osped Bellaria, Bologna, Italy
[2] Univ Perugia, Monteluce Policlin, Perugia, Italy
[3] CINECA, Bologna, Italy
[4] Seconda Univ Napoli, Naples, Italy
[5] Univ Colorado, Ctr Canc, Aurora, CO USA
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：XI25 / XI25
页数：1
相关论文
共 50 条
  • [41] The results of the treatment with gefitinib (Iressa) in 89 patients with advanced non-small cell lung cancer (NSCLC)
    Skrickova, J
    Tomiskova, M
    Svobodnik, A
    Kaplanova, J
    Kadlec, B
    Palkova, I
    Babickova, L
    Stratil, D
    Nebesky, T
    [J]. LUNG CANCER, 2005, 49 : S376 - S376
  • [42] FIRST-LINE GEFITINIB IN EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE (EGFR plus ) NON-SMALL CELL LUNG CANCER (NSCLC) IN AN ISRAELI COHORT
    Ben-Arieh, S.
    Urban, D.
    Maimon, N.
    Leibowitz-Amit, R.
    Keizman, D.
    Biran, H.
    Mishaeli, M.
    Onn, A.
    Gottfried, M.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 29 - 29
  • [43] Comparison of Gefitinib in the treatment of patients with non-small cell lung cancer and clinical effects of Osimertinib and EGFR Gene mutation
    Li, Xiaofeng
    Zhai, Zhanqiang
    Zhu, Youcai
    Zhou, Haiou
    [J]. PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2022, 38 (06) : 1589 - 1594
  • [44] Impact of Patient TKI Copayments on Insurance Expenditure in Advanced EGFR or ALK Positive Non-Small Cell Lung Cancer (NSCLC)
    Goulart, B. Haddock Lobo
    Chennupati, S.
    Egan, K.
    Fedorenko, C.
    Ramsey, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S599 - S599
  • [45] Characteristics of EGFR, ALK, or KRAS Mutant Positive Non-Small Cell Lung Cancer (NSCLC) Patients Treated in a Single Institution
    Chung, E.
    Biswas, T.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E678 - E678
  • [46] Evaluation of Texture Analysis Parameters in EGFR Mutated or ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
    Bluthgen, Maria V.
    Caramella, Caroline
    Rosellini, Silvia
    Leduc, Charlotte
    Facchinetti, Francesco
    Haspinger, Eva
    Ferte, Charles
    Michiels, Stefan
    Soria, Jean C.
    Besse, Benjamin
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S703 - S703
  • [47] A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE
    Tan, Lavinia
    Brown, Chris
    Mersiades, Antony
    Lee, Chee Khoon
    John, Thomas
    Kao, Steven
    Newnham, Genni
    O'Byrne, Kenneth
    Parakh, Sagun
    Bray, Victoria
    Jasas, Kevin
    Yip, Sonia
    Wong, Stephen Q.
    Ftouni, Sarah
    Guinto, Jerick
    Chandrashekar, Sushma
    Clarke, Stephen
    Pavlakis, Nick
    Stockler, Martin R.
    Dawson, Sarah-Jane
    Solomon, Benjamin J.
    [J]. NATURE COMMUNICATIONS, 2024, 15 (01)
  • [48] Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib
    Zucali, Paolo A.
    Giovannetti, Elisa
    Peters, Godefridus
    Cortesi, Filippo
    D'Incecco, Armida
    Smit, Egbert
    Falcone, Alfredo
    Burgers, Sjaak
    Santoro, Armando
    Danesi, Romano
    Giaccone, Giuseppe
    Tibaldi, Carmelo
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S510 - S510
  • [49] Clinical factors affecting the late resistance to gefitinib in patients with non-small cell lung cancer (NSCLC).
    Segawa, Y.
    Hotta, K.
    Umemura, S.
    Fujiwara, Y.
    Shinkai, T.
    Ueoka, H.
    Takigawa, N.
    Tabata, M.
    Kiura, K.
    Tanimoto, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 411S - 411S
  • [50] Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non-Small Cell Lung Cancer Patients Treated with Gefitinib
    Giovannetti, Elisa
    Zucali, Paolo A.
    Peters, Godefridus J.
    Cortesi, Filippo
    D'Incecco, Armida
    Smit, Egbert F.
    Falcone, Alfredo
    Burgers, Jacobus A.
    Santoro, Armando
    Danesi, Romano
    Giaccone, Giuseppe
    Tibaldi, Carmelo
    [J]. MOLECULAR CANCER THERAPEUTICS, 2010, 9 (03) : 581 - 593
12345